Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,501 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stem Cell Clear all
Completed No phase listed Observational

Epidemiology of Diarrheal Diseases in Pediatric Oncology Patients

NCT02464098
View directory record Official record
Conditions
Diarrhea
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 4, 2026, 2:08 AM EDT
Recruiting Phase 1 Interventional

Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT

NCT05095532
View directory record Official record
Conditions
Chronic Pancreatitis, Mesenchymal Stem Cells
Interventions
Bone marrow-derived mesenchymal stem cells, Placebo
Biological · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 4, 2026, 2:08 AM EDT
Completed Phase 3 Interventional

Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

NCT00002649
View directory record Official record
Conditions
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma
Interventions
aldesleukin, filgrastim, cyclophosphamide, etoposide, radiation therapy, peripheral blood stem cell transplantation, bone marrow ablation with stem cell support
Biological · Drug · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 60 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Sep 4, 2026, 2:08 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Stem Cell Transplant for Bone Marrow Failure Syndromes

NCT00176878
View directory record Official record
Conditions
Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome
Interventions
Stem cell transplant, Fludarabine monophosphate, Total lymphoid irradiation, Busulfan, anti-thymocyte globulin
Procedure · Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 35 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 4, 2026, 2:08 AM EDT
Recruiting Phase 2 Interventional

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

NCT06807606
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Drugs Cyclophosphamide, Fludarabine, Thiotepa, Tacrolimus, Mycophenolate mofetil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 4, 2026, 2:08 AM EDT
Completed Phase 1 Interventional

Hematopoietic Stem Cell Transplant Survivors Study

NCT02652052
View directory record Official record
Conditions
Stem Cell Transplant
Interventions
Standard of Care - Observation Only, Group 2: Quercetin, Group 2: Dasatinib
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 4, 2026, 2:08 AM EDT
Completed Not applicable Interventional

Determining The Impact Of Distance Reiki On Patient Reported QOL And Immunity Among Multiple Myeloma Patients

NCT04783038
View directory record Official record
Conditions
Multiple Myeloma, Autologous Stem Cell Transplant
Interventions
Distance Reiki, Sham distance Reiki
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 4, 2026, 2:08 AM EDT
Terminated Phase 2 Interventional Results available

Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma

NCT00006478
View directory record Official record
Conditions
Lymphoma
Interventions
autologous tumor cell vaccine, keyhole limpet hemocyanin, sargramostim, adjuvant therapy
Biological · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 4, 2026, 2:08 AM EDT
Terminated Phase 3 Interventional Results available

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

NCT04161885
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Cancer
Interventions
Venetoclax, Azacitidine, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
43
States / cities
Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 4, 2026, 2:08 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Autologous Bone Marrow Aspirate (IV) and Bone Marrow Concentrate (Intranasal) for Parkinson's Disease and Parkinson-Plus Syndromes (SPARC-PD)

NCT07751640
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Interventions
Autologous Bone Marrow Aspirate (BMA) and Bone Marrow Aspirate Concentrate (BMAC)
Biological
Lead sponsor
Apeiron Research Center
Other
Eligibility
40 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 4, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

Zevalin-beam for Aggressive Lymphoma

NCT00491491
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
ibritumomab tiuxetan, BEAM chemotherapy and autologous stem-cell transplantation
Drug · Procedure
Lead sponsor
Sheba Medical Center
Government
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
6
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Sep 4, 2026, 2:08 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.

NCT00306735
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Palonosetron
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
10
States / cities
Beech Grove, Indiana • New York, New York • Winston-Salem, North Carolina + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 4, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant

NCT01754389
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Tacrolimus, Methotrexate, Bortezomib, Sirolimus
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Sep 4, 2026, 2:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.

NCT03379168
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Microfragmented Adipose Tissue (Lipogems), Corticosteroid injection, Saline
Device · Drug
Lead sponsor
Dustin L. Richter, MD
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 4, 2026, 2:08 AM EDT
Recruiting Phase 1 Interventional

PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy

NCT04837547
View directory record Official record
Conditions
Neuroblastoma, Diffuse Intrinsic Pontine Glioma
Interventions
Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)
Biological
Lead sponsor
University of Florida
Other
Eligibility
1 Year to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
3
States / cities
Gainesville, Florida • Charlotte, North Carolina • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 4, 2026, 2:08 AM EDT
Completed No phase listed Observational

Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation

NCT03072849
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome
Interventions
Pulmonary function testing, FAM Therapy
Procedure · Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
6 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 4, 2026, 2:08 AM EDT
Completed Phase 1Phase 2 Interventional

Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease

NCT00118326
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neuroblastoma, Sarcoma
Interventions
filgrastim, allogeneic bone marrow transplantation
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 13, 2010 · Synced Sep 4, 2026, 2:08 AM EDT
Completed Phase 2 Interventional

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

NCT00066248
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cyproheptadine hydrochloride, megestrol acetate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Sep 4, 2026, 2:08 AM EDT
Completed Phase 1 Interventional

Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV

NCT01535885
View directory record Official record
Conditions
Epstein-Barr Virus Infections, Adenovirus, Cytomegalovirus Infections
Interventions
Cytotoxic T Lymphocytes
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 22 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Sep 4, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma

NCT04552743
View directory record Official record
Conditions
Multiple Myeloma
Interventions
MGTA-145, Plerixafor
Drug
Lead sponsor
Surbhi Sidana, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Sep 4, 2026, 2:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin

NCT00423852
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions
filgrastim, carboplatin, ifosfamide, paclitaxel, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Sep 4, 2026, 2:08 AM EDT
Completed Early Phase 1 Interventional

Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine

NCT01022021
View directory record Official record
Conditions
Lymphoma
Interventions
Rituximab, Bendamustine
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 4, 2026, 2:08 AM EDT
Completed Phase 1 Interventional

Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients

NCT02145325
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Expanded Tregs
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Sep 4, 2026, 2:08 AM EDT